scholarly journals Evaluation of Clinical Utility of the Personal KinetiGraph<sup>&reg;</sup> in the Management of Parkinson Disease

2019 ◽  
Vol 08 (03) ◽  
pp. 42-61 ◽  
Author(s):  
Fatta B. Nahab ◽  
Hamad Abu-Hussain ◽  
Lissette Moreno
Keyword(s):  
Parkinson Disease ◽  
Clinical Utility

Measurement Characteristics and Clinical Utility of the Parkinson Disease Quality of Life Measure (39- and 8-item versions) in Individuals With Parkinson Disease

2015 ◽  
Vol 96 (8) ◽  
pp. 1551-1552 ◽  
Author(s):  
Deborah Kegelmeyer ◽  
Terry Ellis ◽  
Alicia Esposito ◽  
Rosemary Gallagher ◽  
Cathy C. Harro ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Parkinson Disease ◽  
Clinical Utility ◽  
Life Measure

scholarly journals Genetic testing for Parkinson disease

2020 ◽  
pp. 10.1212/CPJ.0000000000000831
Author(s):  
Lola Cook ◽  
Jeanine Schulze ◽  
Catherine Kopil ◽  
Tara Hastings ◽  
Anna Naito ◽  
...  
Keyword(s):  
Genetic Testing ◽  
Parkinson Disease ◽  
Clinical Utility ◽  
Genetic Test ◽  
Genomic Testing ◽  
Test Results ◽  
Genetic Test Results ◽  
Genetic Status ◽  
Genetic Landscape ◽  
Busy Clinician

Purpose of reviewWith the advent of precision medicine and demand for genomic testing information, we may question whether it is time to offer genetic testing to our patients with Parkinson disease (PD). This review updates the current genetic landscape of PD, describes what genetic testing may offer, provides strategies for evaluating whom to test, and provides resources for the busy clinician.Recent findingsPatients with PD and their relatives, in various settings, have expressed an interest in learning their PD genetic status; however, physicians may be hesitant to widely offer testing due to the perceived low clinical utility of PD genetic test results. The rise of clinical trials available for patients with gene-specific PD and emerging information on genotype-phenotype correlations are starting to shift this discussion about testing.SummaryBy learning more about the various genetic testing options for PD and utility of results for patients and their care, clinicians may become more comfortable with widespread PD genetic testing in the research and clinical setting.

Measurement Characteristics and Clinical Utility of the Freezing of Gait Questionnaire in Individuals With Parkinson Disease

2017 ◽  
Vol 98 (10) ◽  
pp. 2106-2107
Author(s):  
Sydney Rozenfeld ◽  
Ana Miskovic ◽  
Kristian P. Nitsch ◽  
Linda Ehrlich-Jones
Keyword(s):  
Parkinson Disease ◽  
Clinical Utility ◽  
Freezing Of Gait

Measurement Characteristics and Clinical Utility of the Mini BESTest in Individuals With Parkinson Disease

2015 ◽  
Vol 96 (7) ◽  
pp. 1367-1368
Author(s):  
Deborah Kegelmeyer ◽  
Terry Ellis ◽  
Alicia Esposito ◽  
Rosemary Gallagher ◽  
Cathy C. Harro ◽  
...  
Keyword(s):  
Parkinson Disease ◽  
Clinical Utility

scholarly journals Pimavanserin (Nuplazid™) for the treatment of Parkinson disease psychosis: A review of the literature

2017 ◽  
Vol 7 (5) ◽  
pp. 230-234 ◽  
Author(s):  
Katie T. B. Touma ◽  
Daniel C. Touma
Keyword(s):  
Parkinson Disease ◽  
Clinical Utility ◽  
Psychotic Symptoms ◽  
Controlled Trials ◽  
Agonist Activity ◽  
Review Of The Literature ◽  
Additional Information ◽  
Randomized Controlled ◽  
Receptor Profile ◽  
Briefing Document

Abstract Introduction: Pimavanserin (Nuplazid™) is an atypical antipsychotic currently indicated for the treatment of hallucinations and delusions associated with Parkinson disease psychosis. The antipsychotic effects of this new agent are believed to occur via selective inverse agonist activity at serotonin 5-HT2a receptors. Methods: Study authors completed a literature review of 2 published randomized controlled trials of pimavanserin for the treatment of Parkinson disease psychosis. The Food and Drug Administration Briefing Document by the Psychopharmacologic Drugs Advisory Committee for the review of pimavanserin dated March 29, 2016, was reviewed for additional information on 2 unpublished trials. Results: Pimavanserin has demonstrated no worsening of motor symptoms of Parkinson disease, but only 1 of 4 trials has shown consistent statistically significant improvements in psychotic symptoms compared with placebo. Discussion: Options for the treatment of Parkinson disease psychosis are limited. The selective receptor profile of pimavanserin offers advantages for tolerability. Further studies are warranted to better provide clinicians and patients with information regarding the clinical utility of this agent.

scholarly journals Psychometric Properties of 3 Functional Mobility Tests for People With Parkinson Disease

2014 ◽  
Vol 94 (2) ◽  
pp. 230-239 ◽  
Author(s):  
Geert Verheyden ◽  
Caroline S. Kampshoff ◽  
Malcolm E. Burnett ◽  
Jessica Cashell ◽  
Louis Martinelli ◽  
...  
Keyword(s):  
Parkinson Disease ◽  
Clinical Utility ◽  
Correlation Coefficients ◽  
Functional Mobility ◽  
Control Group ◽  
Intrarater Reliability ◽  
Yahr Stage ◽  
Mobility Test ◽  
Video Recordings ◽  
Bed Mobility

BackgroundStandardized outcome measures with high clinical utility are of paramount importance for clinical practice.ObjectiveThe purpose of this study was to examine interrater and intrarater reliability, construct validity, discriminant ability, and smallest detectable differences of the sit-to-stand test (STS), Timed “Up & Go” Test (TUG), and bed mobility test for people with Parkinson disease (PD).DesignA cross-sectional, psychometric evaluation study was conducted.MethodsA group of individuals with PD (PD group) and a group of individuals who were healthy (control group) were recruited through local PD groups and assessed in a movement laboratory in their “on” phase. Measurements of time to perform one STS, TUG, and bed mobility test were collected based on video recordings of that single performance.ResultsThirty-eight individuals with PD (Hoehn and Yahr stages I–IV) and 19 age-matched control participants were recruited. Intraclass correlation coefficients for interrater and intrarater reliability for the PD group ranged from .95 to .99. Bland-Altman plots showed mean differences close to zero and narrow confidence intervals. Construct validity was established by means of moderate to good Spearman rho correlation coefficients with part III of the Unified Parkinson's Disease Rating Scale and the Hoehn and Yahr stage (range=.51–.63). Timings of all tests discriminated participants in the PD group from those in the control group and participants in the PD group in Hoehn and Yahr stages I and II from those in Hoehn and Yahr stages III and IV but did not discriminate “nonfallers” or those with single falls from repeat “fallers” or “nonfreezers” from “freezers.” Applicable smallest detectable differences were established.LimitationsThe results are not generalizable to people in the late stage of PD (Hoehn and Yahr stage IV: n=3).ConclusionsTimings of video recordings of 3 functional mobility tests with high clinical utility showed good psychometric properties for community-dwelling, ambulatory people with PD.

Type V Bekesy Pattern: Interpretation and Clinical Utility

1967 ◽  
Vol 10 (4) ◽  
pp. 733-744 ◽  
Author(s):  
William F. Rintelmann ◽  
Earl R. Harford
Keyword(s):  
Clinical Utility ◽  
The Past ◽  
Type V ◽  
Clinical Cases

Recent studies indicate there is some disagreement concerning the interpretation and clinical utility of the Type V Bekesy pattern. Bekesy tracings obtained over the past six years from a sample of clinical cases were analyzed and a definition was established for the Type V pattern. This definition was applied to Bekesy tracings obtained from normal listeners, hypoacusics, and pseudohypoacusics. The Type V pattern was found frequently among pseudohypoacusics and only rarely among other individuals.

“I Can See What You’re Saying”: Clinical Utility of Spectral Moment Analysis

2011 ◽  
Vol 21 (2) ◽  
pp. 44-54
Author(s):  
Kerry Callahan Mandulak
Keyword(s):  
Speech Production ◽  
Speech Signal ◽  
Clinical Utility ◽  
Acoustic Analysis ◽  
Moment Analysis ◽  
Analysis Tool ◽  
Spectral Moment ◽  
Clinical Measure ◽  
Perceptual Analysis ◽  
Disordered Speech

Spectral moment analysis (SMA) is an acoustic analysis tool that shows promise for enhancing our understanding of normal and disordered speech production. It can augment auditory-perceptual analysis used to investigate differences across speakers and groups and can provide unique information regarding specific aspects of the speech signal. The purpose of this paper is to illustrate the utility of SMA as a clinical measure for both clinical speech production assessment and research applications documenting speech outcome measurements. Although acoustic analysis has become more readily available and accessible, clinicians need training with, and exposure to, acoustic analysis methods in order to integrate them into traditional methods used to assess speech production.

Sign in / Sign up

Export Citation Format

Share Document